Santhera Pharmaceuticals Holding AG (0QN1.L)

9,52 -0,01 (-0,09%) In data: 06:03PM BST. Mercato aperto.

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24
Pratteln 4133
Switzerland
41 61 906 89 50
https://www.santhera.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Thomas Meier Ph.D.	Founder & Chairman	83,75k	N/D	1962
Mr. Dario Eklund	Chief Executive Officer	814,82k	N/D	1968
Mr. Andrew P. Smith CGMA, FCMA	Chief Financial Officer	N/D	N/D	1962
Mr. Oliver Strub	General Counsel & Secretary	N/D	N/D	1963
Mr. Günther Metz Ph.D.	Head Business Development	N/D	N/D	1958
Mr. Shabir Hasham M.D.	Chief Medical Officer	N/D	N/D	N/D
Mr. Marc Schrader	Chief Technology Officer	N/D	N/D	N/D
Ms. Eva Kalias	Head of Investor Relations & Communications	N/D	N/D	N/D
Mr. Neville Kodkani M.D.	Head of Global Marketing & Partner Management	N/D	N/D	N/D
Ms. Sarah Holmes-Klotz	Head of People & Culture	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di Santhera Pharmaceuticals Holding AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.